MX2019003544A - Composiciones que comprenden un ligando de union al receptor cannabinoide. - Google Patents

Composiciones que comprenden un ligando de union al receptor cannabinoide.

Info

Publication number
MX2019003544A
MX2019003544A MX2019003544A MX2019003544A MX2019003544A MX 2019003544 A MX2019003544 A MX 2019003544A MX 2019003544 A MX2019003544 A MX 2019003544A MX 2019003544 A MX2019003544 A MX 2019003544A MX 2019003544 A MX2019003544 A MX 2019003544A
Authority
MX
Mexico
Prior art keywords
receptor binding
binding ligand
cannabinoid receptor
compositions
medicament
Prior art date
Application number
MX2019003544A
Other languages
English (en)
Spanish (es)
Inventor
Günther Bernhard
Löscher Frank
Krösser Sonja
Steven Philipp
Original Assignee
Novaliq Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novaliq Gmbh filed Critical Novaliq Gmbh
Publication of MX2019003544A publication Critical patent/MX2019003544A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/02—Halogenated hydrocarbons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/02—Halogenated hydrocarbons
    • A61K31/025—Halogenated hydrocarbons carbocyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/658—Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
MX2019003544A 2016-09-28 2017-09-27 Composiciones que comprenden un ligando de union al receptor cannabinoide. MX2019003544A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP16191194 2016-09-28
EP17168172 2017-04-26
PCT/EP2017/074545 WO2018060282A1 (en) 2016-09-28 2017-09-27 Compositions comprising a cannabinoid receptor binding ligand

Publications (1)

Publication Number Publication Date
MX2019003544A true MX2019003544A (es) 2019-09-19

Family

ID=59966776

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019003544A MX2019003544A (es) 2016-09-28 2017-09-27 Composiciones que comprenden un ligando de union al receptor cannabinoide.

Country Status (10)

Country Link
US (1) US20190343793A1 (enExample)
EP (2) EP3698785A1 (enExample)
JP (1) JP2019534867A (enExample)
KR (1) KR20190060787A (enExample)
CN (1) CN109803650A (enExample)
AU (1) AU2017333420A1 (enExample)
BR (1) BR112019006194A2 (enExample)
CA (1) CA3036313A1 (enExample)
MX (1) MX2019003544A (enExample)
WO (1) WO2018060282A1 (enExample)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101656121B1 (ko) 2010-03-17 2016-09-08 노바리크 게엠베하 안압 증가를 치료하기 위한 약학 조성물
EP2444063A1 (en) 2010-10-20 2012-04-25 Novaliq GmbH Liquid pharmaceutical compositions for the delivery of active ingredients
DK2895144T3 (en) 2012-09-12 2017-03-06 Novaliq Gmbh SEMIFLUORED ALKAN COMPOSITIONS
EP3100722B1 (en) 2012-09-12 2024-03-20 Novaliq GmbH Semifluorinated alkanes for use in solubilizing meibum
US10273298B2 (en) 2013-07-23 2019-04-30 Novaliq Gmbh Stabilized antibody compositions
US11154513B2 (en) 2015-09-30 2021-10-26 Novaliq Gmbh Semifluorinated compounds
US20170087100A1 (en) 2015-09-30 2017-03-30 Novaliq Gmbh Semifluorinated compounds and their compositions
AU2017260444B2 (en) 2016-05-03 2019-05-09 Pneuma Respiratory, Inc. Droplet delivery device for delivery of fluids to the pulmonary system and methods of use
JP2019520357A (ja) 2016-06-23 2019-07-18 ノバリック ゲーエムベーハー 局所投与方法
JP7012075B2 (ja) 2016-09-22 2022-01-27 ノバリック ゲーエムベーハー 眼瞼炎の治療に使用するための医薬組成物
JP6869336B2 (ja) 2016-09-23 2021-05-12 ノバリック ゲーエムベーハー シクロスポリンを含む眼科用組成物
US10732712B2 (en) * 2016-12-27 2020-08-04 Facebook Technologies, Llc Large scale integration of haptic devices
ES2957559T3 (es) 2017-04-21 2024-01-22 Dermaliq Therapeutics Inc Composiciones de yodo
WO2018206656A1 (en) 2017-05-12 2018-11-15 Novaliq Gmbh Pharmaceutical compositions comprosing semifluorinated alkanes for the treatment of contact lense-related conditions
KR20200059272A (ko) 2017-09-27 2020-05-28 노바리크 게엠베하 안구 질환의 치료에서의 사용을 위한 라타노프로스트를 포함하는 안과적 조성물
CN111526914A (zh) 2017-10-04 2020-08-11 精呼吸股份有限公司 电子呼吸致动式直线型液滴输送装置及其使用方法
US11896559B2 (en) 2017-10-04 2024-02-13 Novaliq Gmbh Opthalmic compositions comprising F6H8
EP3706843B1 (en) 2017-11-08 2024-06-26 Pneuma Respiratory, Inc. Electronic breath actuated in-line droplet delivery device with small volume ampoule
JP7353292B2 (ja) 2018-03-02 2023-09-29 ノバリック ゲーエムベーハー ネビボロールを含む医薬組成物
US12226422B2 (en) 2018-04-27 2025-02-18 Novaliq Gmbh Ophthalmic compositions comprising tafluprost for the treatment of glaucoma
CA3112031A1 (en) 2018-10-12 2020-04-16 Novaliq Gmbh Ophthalmic composition for treatment of dry eye disease
CA3128224A1 (en) * 2019-02-01 2020-08-06 Aerie Pharmaceuticals, Inc. Compounds, compositions and methods for treatment of myopia
US12397039B2 (en) 2019-02-13 2025-08-26 Novaliq Gmbh Compositions and methods for the treatment of ocular neovascularization
US12419933B2 (en) 2019-09-06 2025-09-23 Novaliq Gmbh Ophthalmic composition for the treatment of uveitis
EP4203716A1 (en) * 2020-09-24 2023-07-05 Nicoventures Trading Limited Formulation
AU2021358490A1 (en) * 2020-10-05 2023-06-01 Max Biology Co. Ltd. Cannabinoid-containing compositions and use for treating and preventing diseases
US11191751B1 (en) * 2020-10-08 2021-12-07 Ads Therapeutics Llc Topical ophthalmological atropine free base compositions
KR20230142548A (ko) 2021-02-03 2023-10-11 에이디에스 테라퓨틱스 엘엘씨 국소 안과용 조성물
EP4359046B1 (en) 2021-06-22 2025-08-27 Pneuma Respiratory, Inc. Droplet delivery device with push ejection
US20250228876A1 (en) * 2021-10-13 2025-07-17 Pneuma Respiratory, Inc. Compositions for delivery of cannabinoids
CN119768202A (zh) 2022-07-18 2025-04-04 精呼吸股份有限公司 小步长高分辨率气溶胶生成系统及方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19536504C2 (de) * 1995-09-29 1999-09-23 H Meinert Verwendung fluorierter Alkane
CN101516333A (zh) 2006-08-04 2009-08-26 英西斯治疗学股份有限公司 水性屈大麻酚制剂
US8222292B2 (en) 2007-08-06 2012-07-17 Insys Therapeutics, Inc. Liquid cannabinoid formulations
HUE032158T2 (en) 2008-10-31 2017-09-28 Univ Mississippi Process for the preparation of delta9-THC amino acid esters
AT509000B1 (de) * 2009-10-23 2012-12-15 Rausch Peter Wasserlösliche zubereitungen von cannabinoiden und cannabispräparaten und deren anwendungen
EP2335735A1 (en) * 2009-12-14 2011-06-22 Novaliq GmbH Pharmaceutical composition for treatment of dry eye syndrome
EP2444063A1 (en) * 2010-10-20 2012-04-25 Novaliq GmbH Liquid pharmaceutical compositions for the delivery of active ingredients
US8758826B2 (en) 2011-07-05 2014-06-24 Wet Inc. Cannabinoid receptor binding agents, compositions, and methods
EP3100722B1 (en) * 2012-09-12 2024-03-20 Novaliq GmbH Semifluorinated alkanes for use in solubilizing meibum
DK2895144T3 (en) * 2012-09-12 2017-03-06 Novaliq Gmbh SEMIFLUORED ALKAN COMPOSITIONS
WO2015053829A1 (en) 2013-10-09 2015-04-16 Johnson Living Trust Dated October 26, 2001, Leonidas A. Johnson, Trustee Methods and compositions for treating and preventing signs or symptoms of eye disease
ES2784229T3 (es) 2013-11-20 2020-09-23 Panag Pharma Inc Composiciones y procedimientos para el tratamiento de la inflamación y el dolor ocular
MA41299A (fr) 2014-12-30 2017-11-07 Axim Biotechnologies Inc Solutions ophtalmiques pour le traitement du glaucome et de la conjonctivite

Also Published As

Publication number Publication date
KR20190060787A (ko) 2019-06-03
EP3698785A1 (en) 2020-08-26
AU2017333420A1 (en) 2019-04-04
BR112019006194A2 (pt) 2019-06-18
EP3518921A1 (en) 2019-08-07
CA3036313A1 (en) 2018-04-05
JP2019534867A (ja) 2019-12-05
WO2018060282A1 (en) 2018-04-05
US20190343793A1 (en) 2019-11-14
CN109803650A (zh) 2019-05-24
EP3518921B1 (en) 2021-08-11

Similar Documents

Publication Publication Date Title
MX2019003544A (es) Composiciones que comprenden un ligando de union al receptor cannabinoide.
MX2022010168A (es) Moduladores de calpainas y usos terapeuticos de los mismos.
HK1255162A1 (zh) 爱帕琳肽受体激动剂及使用方法
MX2018005340A (es) Proteolisis de direccionamiento a compuestos de quimera y metodos de preparacion y uso de los mismos.
MY195244A (en) Muscarinic Agonists
EP3957723A3 (en) Engineered ligase variants
MX2015017655A (es) Modulador de receptores de estrogeno y uso del mismo.
MX2016014515A (es) Composicion topica de crema gel.
MX2015011132A (es) Moduladores policiclicos del receptor de estrogenos y sus usos.
PH12019502692A1 (en) Anti-cancer combination therapy
IL276888A (en) Pharmaceutical compositions containing timolol
SG10201908839QA (en) 2,4-dihydroxy-nicotinamides as apj agonists
MX2018015125A (es) Nuevos compuestos antibacterianos.
PH12015502523A1 (en) Novel (cyano-dimethyl-methyl)-isoxazoles and -[1,3,4]thiadiazoles
AU2016380190A8 (en) Deuterated compounds for treating cancer and related diseases and conditions, and compositions and methods thereof
EP4331622A3 (en) Integrin binding peptides and uses thereof
MX2017008390A (es) Uretanos funcionalizados con alcoxisilano y funcionalizados con alofanato.
WO2020123753A3 (en) Anellosomes for delivering intracellular therapeutic modalities
AU2018279184A1 (en) Anti-TrkB antibodies
TN2018000057A1 (en) Compounds useful for inhibiting ror-gamma-t.
MX2020005483A (es) Antagonistas de ildr2 y combinaciones de los mismos.
IL277649A (en) Preparations for the treatment of cancer by combining active substances
MX2024003785A (es) Inhibidor de inmunosupresion asociado al cancer.
EP3875091A4 (en) Pharmaceutical composition containing antitumor agent
MY206042A (en) Novel compositions for bitterants